TCR therapy welcomed the first positive Phase 3 results and significantly improved the overall survival rate

The therapy, called tebentafusp, innovatively combines TCR, which targets tumor antigens, with an immune-effect domain that binds to CD3.
designed to guide and activate T-cells, allowing them to identify and kill cancer cells.
The design of such TCR therapies, which simulates the mechanism of natural TCR action (Photo source: Resources) is noteworthy that the company's technology enables TCR to identify cancer antigens in cells with high affinity, which is expected to break through the limitations of existing antibody drugs and increase the number of identifiable targets from 10% to 90%.
In addition, based on existing mechanisms for T-cell immersion of human tumors, Immunocore also points out that its TCR technology is expected to be used to treat immunologically "cold tumors", tumors with low mutation rates that have traditionally been difficult to attract the attention of the immune system.
the therapeutic potential of tebentafusp in a Phase 3 clinical trial.
the trial recruited 378 patients with metastassic staphylocolum melanoma who were divided into two groups by a ratio of 2:1, with the first group receiving tebentafusp and the other using the treatment chosen by the researchers, including dacarbazine, ipilimumumab or pembrolizumab, because of the lack of approved treatments available.
an interim analysis, tebentafusp achieved a significant improvement in total survival, which was also the primary clinical endpoint set in advance.
although the data are not yet fully mature, the tebentafusp group currently has a one-year survival rate of 73 per cent, better than the other treatment groups at 58 per cent.
that the efficacy data is consistent with its Phase 2 clinical, and final data is expected to be published in future scientific meetings and peer-reviewed journals.
"Tebentafusp's positive survival benefits are an important step on the path to potentially innovative therapies for these highly unfinished cancer patients," said Dr. Bahija Jallal, CEO of Immunocore.
is a very low survival rate and in urgent need of innovative therapies.
we look forward to sharing this data with the medical community and health regulators in the future.
" As far as we know, this is the first TCR therapy and dual-specific solid tumor therapy to benefit from survival.
we compared them with immuno-checkpoint inhibitors in randomized clinical trials, the observed survival benefits validated our ImTAC technology platform.
I will continue to study other cancers with high unfinished needs," added Dr. David Berman, head of research and development at Immunocore.
" cancer, Immunocore has a number of other therapies under clinical development, targeting targets such as NY-ESO-1 and MAGE-A4 (Photo source: Immunocore's official website) References: (1) Immunocore's tebentafusp provs superior overall survival compared to investigator's choice in a Phase 3 clinical trial of patients with a previously available u.uly. Retrieved November 23, 2020, from the official website of Immunocore, Retrieved November 23, 2020, from 3] TCR pioneer Immunocore scores a first with a landmark PhIII snapshot on overall survival for a rare melanoma, Retrieved November 23, 2020, from [4] Bertil E. Damato et al., (2019), Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma, Cancers, DOI: